The SMILE study-safety of methotrexate in combination with leflunomide in rheumatoid arthritis

Journal of Rheumatology

Volumn 40, Issue 3, 2013, Pages 228-235

  Bird, Paul ^a   Griffiths, Hedley ^a   Tymms, Kathleen ^a   Nicholls, Dave ^a   Roberts, Lynden ^a   Arnold, Mark ^a   Burnet, Simon ^a   De Jager, Julien ^a   Scott, James ^a   Zochling, Jane ^a   Littlejohn, Geoff ^b  

^a Combined Rheumatology Practice ^*  (Australia)

^b Arthritis Specialist Centre   (Australia)

Author keywords

Leflunomide; Methotrexate; Rheumatoid arthritis

Indexed keywords

LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISONE;

ADULT; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; LIVER DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SIDE EFFECT; SOLID TUMOR;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUSTRALIA; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84874911964     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120922     Document Type: Article

References (17)

1. Lee SS, Park YW, Park JJ, Kang YM, Nam EJ, Kim SI, et al. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Scand J Rheumatol 2009;38:11-4
2. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33
3. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595-603
4. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66
5. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542-50
6. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8
7. National Institutes of Health-National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 4.03,14 June 2010. Washington, DC: U.S. Department of Health and Human Services; 2010. [Internet. Accessed Nov 8, 2012.] Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE- 4.03-2010-06-14-QuickReference-5x7.pdf
8. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75
9. Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: An appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009;32:1123-34
10. Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg JD, Kavanaugh A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010;69:43-7
11. Behrens F, Koehm M, Burkhardt H. Update 2011: Leflunomide in rheumatoid arthritis - strengths and weaknesses. Curr Opin Rheumatol 2011;23:282-7
12. Singer O, Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: What is new in 2011? Curr Opin Rheumatol 2011;23:288-92
13. Mayall B, Poggi G, Parkin JD. Neutropenia due to low-dose methotrexate therapy for psoriasis and rheumatoid arthritis may be fatal. Med J Aust 1991;155:480-4
14. Bourré-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: A systematic review. J Rheumatol 2010;37:1416-21
15. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50
16. Scott DL. Interstitial lung disease and disease modifying anti-rheumatic drugs. Lancet 2004;363:1239-40
17. Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T, et al. Leflunomide-induced interstitial lung disease: Prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology 2009;48:1069-72